肺高血压患者肺血管内皮分子成像:一项II期安全性与概念验证试验
这项II期研究纳入30例肺高血压患者(23例PAH、7例CTEPH)与15名健康对照,评估99mTc-PulmoBind SPECT成像的安全性及检测肺血管疾病的能力。PulmoBind注射耐受良好,无严重不良事件;患者组肺摄取分布指数升高(65%±28% vs 对照41%±13%,p=0.0003),CTEPH者均见段性缺损。作者认为该分子SPECT成像安全并显示检测肺栓塞与PAH肺血管异常的潜力,需III期研究并与肺灌注显像剂直接比较。
要点
- 99mTc-PulmoBind SPECT在肺高血压患者中耐受良好,未发生严重不良事件。
- CTEPH患者7/7见段性缺损,PAH患者2/23见段性缺损,健康对照未见段性缺损。
- PulmoBind活性分布指数在肺高血压组升高(65%±28% vs 对照41%±13%,p=0.0003)。
核心结论
- 在这项II期研究中,使用99mTc-PulmoBind对肺血管内皮进行分子SPECT成像是安全的。
- PulmoBind显示有潜力检测肺栓塞以及提示PAH肺血管疾病的异常。
- 需要开展III期研究,并将该新型示踪剂与肺灌注显像剂(如标记的白蛋白大聚集体)进行直接比较。
研究设计与样本
- II期研究,纳入30例肺高血压患者(PAH 23例、CTEPH 7例;WHO功能分级II级26例、III级4例)与15名健康对照。
- 仰卧位注射15 mCi 99mTc-PulmoBind后行肺SPECT,进行定性与半定量分析。
- 在对照者中于1个月后重复检查以评估重复性。
主要发现
- PulmoBind注射耐受良好,无严重不良事件。
- 肺高血压患者影像明显异常,约50%受试者显示中至重度范围的中至重度异质性。
- 异常在左右肺之间以及每侧肺内分布不均。
- 与肺栓塞相符的段性缺损见于CTEPH 7/7例和PAH 2/23例,健康对照未见段性缺损。
- PulmoBind活性分布指数在肺高血压组为65%±28%,对照为41%±13%(p=0.0003)。
关键数值与推荐
- 注射剂量为15 mCi 99mTc-PulmoBind,仰卧位行肺SPECT。
- PulmoBind活性分布指数:肺高血压组65%±28% vs 对照41%±13%(p=0.0003)。
- 段性缺损:CTEPH 7/7例、PAH 2/23例、健康对照0例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需要开展III期研究,并将该新型示踪剂与肺灌注显像剂(如标记的白蛋白大聚集体)进行直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The adrenomedullin receptor is densely expressed in the pulmonary vascular endothelium. PulmoBind, an adrenomedullin receptor ligand, was developed for molecular diagnosis of pulmonary vascular disease. We evaluated the safety of PulmoBind SPECT imaging and its capacity to detect pulmonary vascular disease associated with pulmonary hypertension (PH) in a human phase II study. METHODS: Thirty patients with pulmonary arterial hypertension (PAH, n = 23) or chronic thromboembolic PH (CTEPH, n = 7) in WHO functional class II (n = 26) or III (n = 4) were compared to 15 healthy controls. Lung SPECT was performed after injection of 15 mCi 99mTc-PulmoBind in supine position. Qualitative and semi-quantitative analyses of lung uptake were performed. Reproducibility of repeated testing was evaluated in controls after 1 month. RESULTS: PulmoBind injection was well tolerated without any serious adverse event. Imaging was markedly abnormal in PH with ∼50% of subjects showing moderate to severe heterogeneity of moderate to severe extent. The abnormalities were unevenly distributed between the right and left lungs as well as within each lung. Segmental defects compatible with pulmonary embolism were present in 7/7 subjects with CTEPH and in 2/23 subjects with PAH. There were no segmental defects in controls. The PulmoBind activity distribution index, a parameter indicative of heterogeneity, was elevated in PH (65% ± 28%) vs. controls (41% ± 13%, p = 0.0003). In the only subject with vasodilator-responsive idiopathic PAH, PulmoBind lung SPECT was completely normal. Repeated testing 1 month later in healthy controls was well tolerated and showed no significant variability of PulmoBind distribution. CONCLUSIONS: In this phase II study, molecular SPECT imaging of the pulmonary vascular endothelium using 99mTc-PulmoBind was safe. PulmoBind showed potential to detect both pulmonary embolism and abnormalities indicative of pulmonary vascular disease in PAH. Phase III studies with this novel tracer and direct comparisons to lung perfusion agents such as labeled macro-aggregates of albumin are needed. CLINICAL TRIAL: ClinicalTrials.gov, NCT02216279.
引用
- Harel F, Langleben D, Provencher S, et al. Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial. Eur J Nucl Med Mol Imaging. 2017. PMID: 28236024. doi:10.1007/s00259-017-3655-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。